Skip to main content
Premium Trial:

Request an Annual Quote

Lonza, SRU Biosystems

Lonza has developed new Amaxa Nucleofector kits for the transfection of primary mouse B cells, from single reactions up to 96-well transfections, the company announced this week.
Results of up to 74 percent transfection efficiency for stimulated mouse B cells and a viability of 59 percent for human hepatocytes 120 hours post nucleofection have been achieved, the company said.
New Amaxa Nucleofector kits are also available for the transfection of human hepatocytes and human chondrocytes.

SRU Biosystems this week announced the launch and first commercial sale of its recently introduced Cartridge Reader to an undisclosed academic laboratory.
The Cartridge Reader is the company’s entry-level instrument for assay development and low-throughput applications to cellular and biochemical studies based on 8- and 16-well label-free biosensors.
The Cartridge Reader can be applied to cell assay development for GPCR, adhesion, and ion channel assays using over-expressed or endogenous systems. In addition, the design of the cartridges and optics of the system allow for the use of low numbers of cells, such as primary cells or stem cells.
The Cartridge Reader can also be used by biochemists and chemists to perform binding analysis of compounds — small molecules or fragments — with target proteins together with SRU’s different surface chemistries. The cartridges are built on standard SRU BIND biosensors and come in a variety of configurations for assay development.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more